

Appendix One: Emetic Potential of Chemotherapy Agents

Minimal Emetic Potential (MinEC)	Low Emetic Potential (LEC)	Moderate Emetic Potential (MEC)	High Emetic Potential (HEC)
Alemtuzumab Asparaginase (IM or IV) ^a Alpha interferon Bevacizumab Bleomycin Bortezomib Chlorambucil (oral) Dasatinib (oral) Decitabine Dexrazoxane Erlotinib (oral) Hydroxyurea (hydroxycarbamide - oral) Melphalan (oral low-dose) Mercaptopurine (oral) Methotrexate (oral) Methotrexate ≤ 50mg/m ² Nelarabine Nilotinib Rituximab Sorafenib (oral) Sunitinib (oral) Tioguanine (oral)	Amifostine ≤ 300mg/m ² Amsacrine ATG Blinatumomab Brentuximab Busulfan (oral) Capecitabine (oral) Cetuximab Cyclophosphamide ≤ 300mg/m ² Cytarabine ≤ 200mg/m ² Dabrafenib (oral) Dinutuximab Everolimus (oral) Fludarabine (oral) 5-Fluorouracil Gemcitabine Gemtuzumab Ibrutinib (oral) Methotrexate > 50mg to < 250mg/m ² Mitomycin Nilotinib (oral) Paclitaxel Pemetrexed Teniposide Thiotepa < 300mg/m ² (approx. < 10mg/kg) Topotecan Triple intrathecal therapy (methotrexate, hydrocortisone & cytarabine) Vorinostat Vinblastine Vincristine Vinorelbine	Aldesleukin > 12 to 15 million units/m ² Amifostine > 300mg/m ² Arsenic trioxide Azacitidine Bendamustine Busulfan Carmustine ≤ 250mg/m ² Cladribine Clofarabine Crizotinib (oral) Cyclophosphamide (oral) Cyclophosphamide < 1 g/m ² Cytarabine > 200mg to < 3g/m ² Daunorubicin (& liposomal) Docetaxel Doxorubicin Epirubicin Etoposide (oral & IV) Idarubicin Ifosfamide Imatinib (oral) Inotuzumab Irinotecan Lomustine (oral) Melphalan > 50 mg/m ² Methotrexate ≥ 250mg to < 12g/m ² Mitozantrone Oxaliplatin > 75mg/m ² Temozolomide (oral) Treosulfan Vinorelbine (oral)	Asparaginase (Erwinia IV) ≥ 20,000 IU/m ² Carboplatin Carmustine > 250mg/m ² Cisplatin Cyclophosphamide ≥ 1 g/m ² Cytarabine ≥ 3g/m ² /day Dacarbazine Dactinomycin (Actinomycin-D) Melphalan Methotrexate ≥ 12g/m ² Procarbazine (oral) Thiotepa ≥ 300mg/m ² (approx. ≥ 10mg/kg) <u>Combination Regimens:</u> Cyclophosphamide & anthracycline (doxorubicin, daunorubicin, epirubicin, idarubicin) Cyclophosphamide & etoposide Cytarabine 150-200mg/m ² & daunorubicin Cytarabine 300mg/m ² & etoposide Cytarabine 300mg/m ² & teniposide Doxorubicin & ifosfamide Doxorubicin & methotrexate 5g/m ² Ifosfamide & etoposide

Note: Table is intended as a guide only; all agents given intravenously (IV) unless stated otherwise

^a Exception IV Asparaginase (Erwinia)

Adapted from Children's Oncology Group (2022) & Sing et al (2019)